or Try an Advanced Search...

    Alnylam Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    ALNY D Alnylam Pharmaceuticals, Inc. 1.34
    PRQR D ProQR Therapeutics B.V. 1.01
    RGLS B Regulus Therapeutics Inc. -1.49
    VIR C Vir Biotechnology, Inc. 13.18
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm

    Related ETFs - A few ETFs which own one or more of the above listed Alnylam Pharmaceuticals stocks.

    Symbol Grade Name Weight
    GERM C ETFMG Treatments Testing and Advancements ETF 9.0
    GNOM D Global X Genomics & Biotechnology ETF 4.72
    BTEC C Principal Healthcare Innovators Index ETF 3.53
    FBT D First Trust Amex Biotech Index Fund 3.37
    IBBQ C Invesco Nasdaq Biotechnology ETF 2.17
    View all Alnylam Pharmaceuticals ETFs...
    Compare ETFs
    Compare BTEC to FBT Compare GERM to GNOM Compare GNOM to BTEC

        Alnylam Pharmaceuticals Stocks Recent News

        Date Stock Title
        May 3 VIR Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2024 Earnings Call Transcript
        May 3 ALNY Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
        May 3 VIR Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders
        May 3 ALNY Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
        May 3 ALNY Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations
        May 3 VIR Q1 2024 Vir Biotechnology Inc Earnings Call
        May 3 VIR Vir Biotechnology Inc (VIR) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
        May 3 ALNY Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...
        May 3 VIR Vir Biotechnology, Inc. (VIR) Q1 2024 Earnings Call Transcript
        May 2 VIR Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
        May 2 VIR Vir Biotechnology GAAP EPS of -$0.48 beats by $0.59, revenue of $56.38M beats by $44.67M
        May 2 VIR Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
        May 2 ALNY Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2024 Earnings Call Transcript
        May 2 ALNY Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 2 ALNY Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics
        May 2 ALNY Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates
        May 2 ALNY Alnylam Pharmaceuticals Non-GAAP EPS of -$0.16 beats by $0.32, revenue of $494.3M beats by $67.44M
        May 2 ALNY Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
        May 1 VIR Vir Biotechnology Q1 2024 Earnings Preview
        May 1 ALNY Alnylam Pharmaceuticals Q1 2024 Earnings Preview
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm
        Alnylam Pharmaceuticals

        Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

        More about Alnylam Pharmaceuticals
        Browse All Tags